Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. The company offers pharmaceutical products in the areas of anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory, narcotic analgesics, endocrine system, enteral parenteral,… Read more
Xizang Haisco Pharmaceutical Group Co Ltd (002653) - Net Assets
Latest net assets as of September 2025: CN¥4.23 Billion CNY
Based on the latest financial reports, Xizang Haisco Pharmaceutical Group Co Ltd (002653) has net assets worth CN¥4.23 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.21 Billion) and total liabilities (CN¥2.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.23 Billion |
| % of Total Assets | 58.57% |
| Annual Growth Rate | 20.42% |
| 5-Year Change | 47.2% |
| 10-Year Change | 94.85% |
| Growth Volatility | 63.17 |
Xizang Haisco Pharmaceutical Group Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual net assets of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.20 Billion | +0.76% |
| 2023-12-31 | CN¥4.17 Billion | +33.10% |
| 2022-12-31 | CN¥3.13 Billion | +7.30% |
| 2021-12-31 | CN¥2.92 Billion | +2.29% |
| 2020-12-31 | CN¥2.85 Billion | +20.12% |
| 2019-12-31 | CN¥2.38 Billion | +19.17% |
| 2018-12-31 | CN¥1.99 Billion | +1.22% |
| 2017-12-31 | CN¥1.97 Billion | -12.99% |
| 2016-12-31 | CN¥2.26 Billion | +5.01% |
| 2015-12-31 | CN¥2.16 Billion | +2.34% |
| 2014-12-31 | CN¥2.11 Billion | +9.36% |
| 2013-12-31 | CN¥1.93 Billion | +12.83% |
| 2012-12-31 | CN¥1.71 Billion | +122.44% |
| 2011-12-31 | CN¥767.76 Million | +69.45% |
| 2010-12-31 | CN¥453.09 Million | +235.19% |
| 2009-12-31 | CN¥135.17 Million | -37.12% |
| 2008-12-31 | CN¥214.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xizang Haisco Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 809.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.76 Billion | 41.69% |
| Common Stock | CN¥1.12 Billion | 26.58% |
| Other Comprehensive Income | CN¥492.94 Million | 11.70% |
| Other Components | CN¥843.75 Million | 20.03% |
| Total Equity | CN¥4.21 Billion | 100.00% |
Xizang Haisco Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Xizang Haisco Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AMP Limited
F:AMP
|
$1.88 Billion |
|
Ningbo Ronbay New Energy Tech Ltd
SHG:688005
|
$1.88 Billion |
|
Morinaga Milk Industry Co. Ltd
F:MO8
|
$1.88 Billion |
|
ArcBest Corp
NASDAQ:ARCB
|
$1.88 Billion |
|
Capital & Counties Properties PLC
PINK:CCPPF
|
$1.88 Billion |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
$1.87 Billion |
|
Guangdong Aofei Data Technology Co Ltd Class A
SHE:300738
|
$1.87 Billion |
|
Hindustan Copper Limited
NSE:HINDCOPPER
|
$1.87 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xizang Haisco Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,179,894,703 to 4,213,333,603, a change of 33,438,900 (0.8%).
- Net income of 395,455,242 contributed positively to equity growth.
- Dividend payments of 422,042,298 reduced retained earnings.
- Other comprehensive income increased equity by 49,029,819.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥395.46 Million | +9.39% |
| Dividends Paid | CN¥422.04 Million | -10.02% |
| Other Comprehensive Income | CN¥49.03 Million | +1.16% |
| Other Changes | CN¥11.00 Million | +0.26% |
| Total Change | CN¥- | 0.80% |
Book Value vs Market Value Analysis
This analysis compares Xizang Haisco Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 214.29x to 13.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.24 | CN¥50.72 | x |
| 2009-12-31 | CN¥0.15 | CN¥50.72 | x |
| 2010-12-31 | CN¥0.48 | CN¥50.72 | x |
| 2011-12-31 | CN¥0.79 | CN¥50.72 | x |
| 2012-12-31 | CN¥1.58 | CN¥50.72 | x |
| 2013-12-31 | CN¥1.78 | CN¥50.72 | x |
| 2014-12-31 | CN¥1.96 | CN¥50.72 | x |
| 2015-12-31 | CN¥2.03 | CN¥50.72 | x |
| 2016-12-31 | CN¥2.10 | CN¥50.72 | x |
| 2017-12-31 | CN¥1.84 | CN¥50.72 | x |
| 2018-12-31 | CN¥1.89 | CN¥50.72 | x |
| 2019-12-31 | CN¥2.22 | CN¥50.72 | x |
| 2020-12-31 | CN¥2.71 | CN¥50.72 | x |
| 2021-12-31 | CN¥2.64 | CN¥50.72 | x |
| 2022-12-31 | CN¥2.82 | CN¥50.72 | x |
| 2023-12-31 | CN¥3.82 | CN¥50.72 | x |
| 2024-12-31 | CN¥3.76 | CN¥50.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xizang Haisco Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.39%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.63%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.61x
- Recent ROE (9.39%) is below the historical average (36.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 90.76% | 54.99% | 1.00x | 1.65x | CN¥173.59 Million |
| 2009 | 209.89% | 58.55% | 1.39x | 2.58x | CN¥270.20 Million |
| 2010 | 67.48% | 52.57% | 0.92x | 1.39x | CN¥260.44 Million |
| 2011 | 40.68% | 51.67% | 0.68x | 1.15x | CN¥235.52 Million |
| 2012 | 25.94% | 55.24% | 0.41x | 1.14x | CN¥272.28 Million |
| 2013 | 26.95% | 52.32% | 0.40x | 1.28x | CN¥326.52 Million |
| 2014 | 21.38% | 37.22% | 0.42x | 1.36x | CN¥239.80 Million |
| 2015 | 17.26% | 30.69% | 0.38x | 1.50x | CN¥156.50 Million |
| 2016 | 19.55% | 30.84% | 0.39x | 1.64x | CN¥216.32 Million |
| 2017 | 11.96% | 12.80% | 0.45x | 2.07x | CN¥38.99 Million |
| 2018 | 16.44% | 9.72% | 0.78x | 2.15x | CN¥130.56 Million |
| 2019 | 20.83% | 12.54% | 0.78x | 2.12x | CN¥256.76 Million |
| 2020 | 21.93% | 19.12% | 0.67x | 1.72x | CN¥346.38 Million |
| 2021 | 12.14% | 12.44% | 0.55x | 1.76x | CN¥60.87 Million |
| 2022 | 9.13% | 9.19% | 0.50x | 1.99x | CN¥-26.50 Million |
| 2023 | 7.06% | 8.80% | 0.50x | 1.59x | CN¥-122.88 Million |
| 2024 | 9.39% | 10.63% | 0.55x | 1.61x | CN¥-25.88 Million |
Industry Comparison
This section compares Xizang Haisco Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xizang Haisco Pharmaceutical Group Co Ltd (002653) | CN¥4.23 Billion | 90.76% | 0.71x | $1.88 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |